EE04552B1 - Naatriumalendronaadi hdraadivormid, nende valmistamismeetodid ja neid sisaldavadfarmatseutilised kompositsioonid - Google Patents
Naatriumalendronaadi hdraadivormid, nende valmistamismeetodid ja neid sisaldavadfarmatseutilised kompositsioonidInfo
- Publication number
- EE04552B1 EE04552B1 EEP200100126A EEP200100126A EE04552B1 EE 04552 B1 EE04552 B1 EE 04552B1 EE P200100126 A EEP200100126 A EE P200100126A EE P200100126 A EEP200100126 A EE P200100126A EE 04552 B1 EE04552 B1 EE 04552B1
- Authority
- EE
- Estonia
- Prior art keywords
- processes
- alendronate sodium
- pharmaceutical compositions
- preparation
- sodium salt
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- DCSBSVSZJRSITC-UHFFFAOYSA-M alendronate sodium trihydrate Chemical group O.O.O.[Na+].NCCCC(O)(P(O)(O)=O)P(O)([O-])=O DCSBSVSZJRSITC-UHFFFAOYSA-M 0.000 title 1
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 abstract 3
- 229960004343 alendronic acid Drugs 0.000 abstract 3
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 208000006386 Bone Resorption Diseases 0.000 abstract 1
- 208000020084 Bone disease Diseases 0.000 abstract 1
- 230000024279 bone resorption Effects 0.000 abstract 1
- 238000010348 incorporation Methods 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3839—Polyphosphonic acids
- C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9831398P | 1998-08-27 | 1998-08-27 | |
| US12974399P | 1999-04-16 | 1999-04-16 | |
| US14446199P | 1999-07-19 | 1999-07-19 | |
| PCT/US1999/019838 WO2000012517A1 (en) | 1998-08-27 | 1999-08-27 | Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EE200100126A EE200100126A (et) | 2002-06-17 |
| EE04552B1 true EE04552B1 (et) | 2005-10-17 |
Family
ID=27378576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EEP200100126A EE04552B1 (et) | 1998-08-27 | 1999-08-27 | Naatriumalendronaadi hdraadivormid, nende valmistamismeetodid ja neid sisaldavadfarmatseutilised kompositsioonid |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US6281381B1 (xx) |
| EP (1) | EP1107974B1 (xx) |
| JP (2) | JP2002523514A (xx) |
| KR (2) | KR20010079701A (xx) |
| AT (1) | ATE334993T1 (xx) |
| AU (1) | AU5698899A (xx) |
| BG (1) | BG65329B1 (xx) |
| BR (1) | BR9913472A (xx) |
| CA (1) | CA2341459A1 (xx) |
| CZ (1) | CZ2001629A3 (xx) |
| DE (1) | DE69932620T2 (xx) |
| DK (1) | DK1107974T3 (xx) |
| EA (1) | EA002739B1 (xx) |
| EE (1) | EE04552B1 (xx) |
| ES (1) | ES2270613T3 (xx) |
| HR (1) | HRP20010129A2 (xx) |
| HU (1) | HUP0203078A3 (xx) |
| IL (1) | IL141423A (xx) |
| IS (1) | IS5864A (xx) |
| LT (1) | LT4888B (xx) |
| LV (1) | LV12720B (xx) |
| NO (1) | NO20010957L (xx) |
| NZ (1) | NZ510682A (xx) |
| PL (1) | PL346347A1 (xx) |
| PT (1) | PT1107974E (xx) |
| RO (1) | RO122854B1 (xx) |
| SI (1) | SI20581B (xx) |
| SK (1) | SK2482001A3 (xx) |
| WO (1) | WO2000012517A1 (xx) |
| YU (1) | YU14701A (xx) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2451881A1 (fr) * | 2001-07-16 | 2003-01-30 | Universite Paris 13 | Nouveaux derives de bisphosphonates, leurs preparations et utilisations |
| GB2383042A (en) | 2001-10-18 | 2003-06-18 | Cipla Ltd | Amorphous alendronate sodium |
| US20040052843A1 (en) * | 2001-12-24 | 2004-03-18 | Lerner E. Itzhak | Controlled release dosage forms |
| EP2172192A1 (en) * | 2001-12-24 | 2010-04-07 | Teva Pharmaceutical Industries Ltd. | Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder of granular material, and process and tooling for producing it |
| ITMI20020146A1 (it) * | 2002-01-29 | 2003-07-29 | Lyogen Ltd | Alendronato monosodico amorfo e processo per la sua preparazione |
| JP2005531532A (ja) * | 2002-04-05 | 2005-10-20 | メルク エンド カムパニー インコーポレーテッド | アレンドロナートおよびビタミンｄ製剤を用いる骨吸収阻害法 |
| US20080249068A1 (en) * | 2002-09-05 | 2008-10-09 | Deluca Hector F | Method of Extending the Dose Range of Vitamin D Compounds |
| US20050113343A1 (en) * | 2003-10-14 | 2005-05-26 | Pliva - Research And Development Ltd. | Solid-state form of alendronate sodium and preparation thereof |
| US20050181043A1 (en) * | 2004-02-12 | 2005-08-18 | Indranil Nandi | Alendronate salt tablet compositions |
| US20050261250A1 (en) * | 2004-05-19 | 2005-11-24 | Merck & Co., Inc., | Compositions and methods for inhibiting bone resorption |
| WO2005115331A2 (en) | 2004-05-24 | 2005-12-08 | The Procter & Gamble Company | Enteric solid oral dosage form of bisphosphonate containing a chelating agent |
| CZ296937B6 (cs) * | 2004-09-02 | 2006-07-12 | Zentiva, A. S | Trisodná sul kyseliny 4-amino-1-hydroxybutyliden-1,1-bisfosfonové |
| ATE440888T1 (de) * | 2004-10-29 | 2009-09-15 | Sandoz Ag | Verfahren zur herstellung von glatiramer |
| US20060134190A1 (en) * | 2004-12-16 | 2006-06-22 | Banner Pharmacaps Inc. | Formulations of bisphosphonate drugs with improved bioavailability |
| CZ297262B6 (cs) * | 2004-12-28 | 2006-10-11 | Zentiva, A. S. | Trisodná sul kyseliny 4-amino-1-hydroxybutyliden-1,1-bisfosfonové |
| US8003820B2 (en) * | 2005-10-20 | 2011-08-23 | Dr. Reddy's Laboratories Limited | Process for preparing bisphosphonic acids |
| AR058168A1 (es) * | 2005-11-07 | 2008-01-23 | Merck & Co Inc | Sintesis del alendronato de sodio trihidratado |
| JP5523833B2 (ja) * | 2006-10-27 | 2014-06-18 | シグナル ファーマシューティカルズ，エルエルシー | ４−［９−（テトラヒドロ−フラン−３−イル）−８−（２，４，６−トリフルオロ−フェニルアミノ）−９ｈ−プリン−２−イルアミノ］−シクロヘキサン−１−オールを含む固体形態、それらの組成物、及びそれらの使用 |
| ES2392890T3 (es) * | 2006-11-22 | 2012-12-14 | Eisai R&D Management Co., Ltd. | Sal sódica de un compuesto disacarídico, procedimiento para la producción de la misma y uso de la misma |
| US20090076144A1 (en) * | 2007-09-17 | 2009-03-19 | Protia, Llc | Deuterium-enriched bazedoxifene |
| US20090118238A1 (en) * | 2007-09-17 | 2009-05-07 | Protia, Llc | Deuterium-enriched alendronate |
| US20090170815A1 (en) * | 2007-12-28 | 2009-07-02 | Roxane Laboratories Incorporated. | Alendronate oral liquid formulations |
| JP2013510097A (ja) * | 2009-11-03 | 2013-03-21 | リウ、リー | タンシノンｉｉａスルホン酸ナトリウム水和物、並びにその調製方法及び使用 |
| RU2021125455A (ru) | 2013-11-15 | 2021-10-05 | Экебиа Терапьютикс, Инк. | Твердые формы { [5-(3-хлорфенил)-3-гидроксипиридин-2-карбонил]амино} уксусной кислоты, их композиции и применения |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3016289A1 (de) | 1980-04-28 | 1981-10-29 | Henkel KGaA, 4000 Düsseldorf | Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren |
| IT1201087B (it) * | 1982-04-15 | 1989-01-27 | Gentili Ist Spa | Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche |
| US4639338A (en) * | 1984-08-06 | 1987-01-27 | Ciba-Geigy Corporation | Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate |
| DE3434667A1 (de) | 1984-09-21 | 1986-04-03 | Henkel KGaA, 4000 Düsseldorf | 4-dimethylamino-1-hydroxybutan-1,1-diphosphonsaeure, deren wasserloesliche salze, verfahren zu ihrer herstellung sowie ihre verwendung |
| IT1196315B (it) * | 1984-10-29 | 1988-11-16 | Gentili Ist Spa | Procedimento per la preparazione di acidi difosfonici |
| US4711800A (en) * | 1985-06-06 | 1987-12-08 | Divincenzo Maureen | Needlecraft with metallic substrate |
| US4922007A (en) * | 1989-06-09 | 1990-05-01 | Merck & Co., Inc. | Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof |
| US5019651A (en) * | 1990-06-20 | 1991-05-28 | Merck & Co., Inc. | Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof |
| US5039819A (en) | 1990-09-18 | 1991-08-13 | Merck & Co., Inc. | Diphosphonate intermediate for preparing an antihypercalcemic agent |
| US5159108A (en) | 1990-09-18 | 1992-10-27 | Merck & Co., Inc. | Process for preparing an antihypercalcemic agent |
| JPH11506757A (ja) * | 1995-06-06 | 1999-06-15 | メルク エンド カンパニー インコーポレーテッド | 二ナトリウムアレンドロネート製剤 |
| CA2221417C (en) * | 1995-06-06 | 2002-04-30 | Merck & Co., Inc. | Anhydrous alendronate monosodium salt formulations |
-
1999
- 1999-08-27 DK DK99944004T patent/DK1107974T3/da active
- 1999-08-27 ES ES99944004T patent/ES2270613T3/es not_active Expired - Lifetime
- 1999-08-27 RO ROA200100219A patent/RO122854B1/ro unknown
- 1999-08-27 SK SK248-2001A patent/SK2482001A3/sk unknown
- 1999-08-27 NZ NZ510682A patent/NZ510682A/en not_active IP Right Cessation
- 1999-08-27 BR BR9913472-1A patent/BR9913472A/pt not_active Application Discontinuation
- 1999-08-27 CA CA002341459A patent/CA2341459A1/en not_active Abandoned
- 1999-08-27 US US09/384,145 patent/US6281381B1/en not_active Expired - Fee Related
- 1999-08-27 JP JP2000567539A patent/JP2002523514A/ja not_active Withdrawn
- 1999-08-27 AU AU56988/99A patent/AU5698899A/en not_active Abandoned
- 1999-08-27 AT AT99944004T patent/ATE334993T1/de not_active IP Right Cessation
- 1999-08-27 SI SI9920070A patent/SI20581B/sl not_active IP Right Cessation
- 1999-08-27 DE DE69932620T patent/DE69932620T2/de not_active Expired - Fee Related
- 1999-08-27 WO PCT/US1999/019838 patent/WO2000012517A1/en not_active Application Discontinuation
- 1999-08-27 KR KR1020017002535A patent/KR20010079701A/ko active Search and Examination
- 1999-08-27 HU HU0203078A patent/HUP0203078A3/hu unknown
- 1999-08-27 IL IL14142399A patent/IL141423A/xx not_active IP Right Cessation
- 1999-08-27 EP EP99944004A patent/EP1107974B1/en not_active Expired - Lifetime
- 1999-08-27 YU YU14701A patent/YU14701A/sh unknown
- 1999-08-27 CZ CZ2001629A patent/CZ2001629A3/cs unknown
- 1999-08-27 EA EA200100184A patent/EA002739B1/ru not_active IP Right Cessation
- 1999-08-27 PT PT99944004T patent/PT1107974E/pt unknown
- 1999-08-27 PL PL99346347A patent/PL346347A1/xx not_active Application Discontinuation
- 1999-08-27 KR KR1020077004456A patent/KR20070034132A/ko not_active Application Discontinuation
- 1999-08-27 EE EEP200100126A patent/EE04552B1/xx not_active IP Right Cessation
-
2001
- 2001-02-22 HR HR20010129A patent/HRP20010129A2/hr not_active Application Discontinuation
- 2001-02-26 IS IS5864A patent/IS5864A/is unknown
- 2001-02-26 LT LT2001016A patent/LT4888B/lt not_active IP Right Cessation
- 2001-02-26 NO NO20010957A patent/NO20010957L/no not_active Application Discontinuation
- 2001-02-26 BG BG105292A patent/BG65329B1/bg unknown
- 2001-04-05 LV LVP-01-26A patent/LV12720B/en unknown
- 2001-07-03 US US09/898,756 patent/US6696601B2/en not_active Expired - Fee Related
-
2009
- 2009-02-18 JP JP2009035788A patent/JP2009143955A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EE04552B1 (et) | Naatriumalendronaadi hdraadivormid, nende valmistamismeetodid ja neid sisaldavadfarmatseutilised kompositsioonid | |
| MY119970A (en) | Method of fertilizing an avian egg in the shell | |
| AU7642001A (en) | Novel $G(Y) crystalline form of perindopril tert-butylamine salt, preparation method, and pharmaceutical compositions containing same. | |
| MY119968A (en) | Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1, 1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate | |
| EE04463B1 (et) | 3-arüülpropaanhappe derivaadid ja nende analoogid, nende valmistamise meetod, neid sisaldavad ravimkoostised ja ühendid kasutamiseks ravis | |
| HUP0102813A3 (en) | New betha crystalline form of perindopril tert-butylamine salt, process for its preparation and pharmaceutical compositions containing it | |
| AU2001276419A1 (en) | Novel beta crystalline form of perindopril tert- butylamine salt, preparation method and pharmaceutical compositions containing same | |
| PT1051159E (pt) | Composicoes farmaceuticas solidas contendo miltefosina para administracao oral no tratamento de leishmaniose | |
| HUP0402391A3 (en) | Crystalline sodium salt of telmisartan, process for its production and pharmaceutical compositions containing it | |
| BR9915729A (pt) | Amidas Èmega de n-arilsulfonil-aminoácido | |
| NO20002962L (no) | FremgangsmÕte for fremstilling av fludarabinfosfatlium-, - natrium-, -kalium-, -kalsium- og -magnesiumsalter, fremgangsmÕte for rensing av fludarabinfosfat, og fludarabinfosfat som er minst 99,5% rent | |
| EP1702924A3 (en) | Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof | |
| HU0102815D0 (en) | New alpha crystalline form of perindopril tert-butylamine salt, process for its preparation and pharmaceutical compositions containing it | |
| ZA200101451B (en) | Hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HD1A | Correction of address | ||
| KB4A | Valid patent at the end of a year |
Effective date: 20051231 |
|
| KB4A | Valid patent at the end of a year |
Effective date: 20061231 |
|
| KB4A | Valid patent at the end of a year |
Effective date: 20071231 |
|
| KB4A | Valid patent at the end of a year |
Effective date: 20081231 |
|
| MM4A | Lapsed by not paying the annual fees |
Effective date: 20090827 |